Accelerate Technological Breakthroughs in Product Innovation and Promote the Industrialization and Application of Innovative Drugs

Promote enterprises to focus on unmet clinical needs and increase investment in the development of innovative products. Support enterprises to focus on new targets and new mechanisms based on local resources and advantages, and to face the global market Carry out R&D layout and actively lead innovation. Promote innovation in traditional Chinese medicine and develop products that are compatible with the clinical positioning of traditional Chinese medicine, reflecting its characteristics and The Chinese medicine industry has been developing new drugs that are compatible with its clinical positioning and reflect its characteristics and advantages. Improve the clinical value-oriented drug clinical research and development guidelines, strengthen information guidance, and promote the rational layout of R&D pipelines by enterprises. For The 14th Five-Year Plan provides detailed guidance for different types of drugs, and defines the direction of innovation. Development directions:

Chemical Medicine

Focuses on the development of a range of products that address the major clinical needs of tumours, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases, diabetes, hepatitis, respiratory diseases, drug-resistant microbial infections and other major clinical needs. and rare diseases with new targets and new mechanisms. The development of antisense oligonucleotide, small interfering RNA The development of drugs based on novel technology platforms such as antisense oligonucleotides, small interfering RNAs and protein degradation technology (PROTAC). To develop precision therapeutics for specific disease subgroups based on the progress of disease segmentation and the need for precision medicine. To develop improved drugs with clear clinical value. Development of new and improved drugs with clear clinical value. 

Traditional Chinese Medicine

The development of new Chinese medicines will be guided by clinical value and will be carried out in a variety of ways, such as the combination of disease and evidence, specific medicine for specific diseases or evidence-based Chinese medicines. The development of new Chinese medicines will be carried out in various ways, with emphasis on the development of compound preparations based on ancient classical prescriptions, and the transformation of Chinese medicine preparations in medical institutions into new Chinese medicines. and the transformation of Chinese medicine preparations in medical institutions into new Chinese medicine; in-depth research on the effective substances and pharmacology and toxicology of Chinese medicine We will also carry out basic research on the effective substances and pharmacology and toxicology of Chinese medicines; carry out secondary development of proprietary Chinese medicines and develop large varieties of Chinese medicines. 

Biological Drug

In the field of antibody drugs, the focus is on the development of new antibody drugs for tumors, immune diseases, viral infections, hyperlipidemia and other diseases. The development of new antibody drugs for diseases such as oncology, immune diseases, viral infections, hyperlipidemia, new generation of immune detection site modulators, multifunctional antibodies, GPCR antibodies, antibody-coupled drugs (ADCs), and the development of antibodies and other drugs. G protein-coupled receptor (GPCR) antibodies, antibody-coupled drugs (ADCs), and the development of combination therapies between antibodies and other drugs. The development of combination therapies between antibodies and other drugs. In the field of vaccines, the focus will be on the development of novel neo-coronavirus vaccines, herpes vaccines, multivalent human papillomavirus (HPV) vaccines, and vaccines for the treatment of the disease. HPV vaccine and multi-drug polyvalent vaccines. In the field of recombinant protein drugs In the field of recombinant protein drugs, the focus will be on the development of innovative drugs with new targets, as well as the upgrading of listed drugs using long-acting technologies and new routes of administration. In the field of recombinant protein drugs, the focus will be on the development of innovative drugs with new targets, as well as the upgrading of listed drugs using long-acting technologies and new drug delivery routes. In other areas, the focus will be on the development of chimeric antigen receptor T In other areas, we will focus on the development of chimeric antigen receptor T cells (CAR-T), chimeric antigen receptor NK cells (CAR-NK), etc. for new targets and indications. immune cell therapy, stem cell therapy, gene therapy products and specific immunoglobulins.